Uproleselan sodium is a small molecule commercialized by GlycoMimetics, with a leading Phase III program in Relapsed Acute Myeloid Leukemia. According to Globaldata, it is involved in 15 clinical trials, of which 7 were completed, 7 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Uproleselan sodium’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Uproleselan sodium is expected to reach an annual total of $183 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Uproleselan sodium Overview
Uproleselan sodium (GMI-1271) is under the development for the treatment of acute myeloid leukemia (AML), coronavirus disease 2019 (COVID-19) pneumonia, myelodysplastic syndrome, chronic myelogenous leukemia and Inflammatory diseases. The drug candidate is administered through intravenous route. It acts by targeting E-selectin. GMI-1271 is a mimetic of naturally occurring carbohydrate (GlycoMimetics). It was also under development for deep venous thrombosis, pancreatic cancer, multiple myeloma and breast cancer.
GlycoMimetics is a clinical-stage biotechnology company that discovers and develops small molecule drugs for the treatment of cancer and inflammatory diseases. The company’s lead pipeline product, uproleselan, is being developed for the treatment of relapsed/refractory acute myeloid leukemia (AML) in adults. GlycoMimetics designs galectin inhibitors for advancing treatment options for various diseases. The company designs and tests viral and bacterial entry inhibitors for dendritic cell receptors. The company uses proprietary glycobiology technology to develop treatments for diseases. It also offers clinical research programs. GlycoMimetics is headquartered in Rockville, Maryland, the US.
The company reported revenues of (US Dollars) US$0.1 million for the fiscal year ended December 2022 (FY2022), a decrease of 93.5% over FY2021. The operating loss of the company was US$47.4 million in FY2022, compared to an operating loss of US$63.5 million in FY2021. The net loss of the company was US$46.7 million in FY2022, compared to a net loss of US$63.4 million in FY2021.
For a complete picture of Uproleselan sodium’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.